Compare RGR & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGR | CTMX |
|---|---|---|
| Founded | 1949 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 521.9M | 596.2M |
| IPO Year | 1994 | 2015 |
| Metric | RGR | CTMX |
|---|---|---|
| Price | $36.44 | $5.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $8.86 |
| AVG Volume (30 Days) | 127.5K | ★ 3.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.88% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $535,643,000.00 | $138,103,000.00 |
| Revenue This Year | $0.73 | N/A |
| Revenue Next Year | $2.27 | N/A |
| P/E Ratio | ★ N/A | $22.58 |
| Revenue Growth | N/A | ★ 36.45 |
| 52 Week Low | $28.33 | $0.40 |
| 52 Week High | $48.21 | $6.35 |
| Indicator | RGR | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 44.63 | 57.58 |
| Support Level | $36.41 | $5.10 |
| Resistance Level | $38.37 | $6.25 |
| Average True Range (ATR) | 1.11 | 0.40 |
| MACD | -0.22 | -0.04 |
| Stochastic Oscillator | 5.25 | 67.29 |
Sturm Ruger & Co Inc and its subsidiary are principally engaged in the design, manufacture, and sale of firearms to domestic customers. The company's design and manufacturing operations are in the United States and almost all product content is domestic. The company has two reportable operating segments: firearms and castings. The firearms segment manufactures and sells rifles, pistols, and revolvers principally to a number of federally-licensed, independent wholesale distributors located in the United States. The castings segment manufactures and sells steel investment castings and metal injection molding parts. It generates maximum income from the sale of Firearms.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.